- Home
- M vs LQDA Comparison
M vs LQDA Comparison
Compare M & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | M | LQDA |
|---|---|---|
| Founded | 1830 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 5.5B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | M | LQDA |
|---|---|---|
| Price | $23.35 | $81.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | $20.09 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 6.3M | 2.4M |
| Earning Date | 05-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | 12.08 | ★ 51.81 |
| EPS | 0.23 | ★ 0.52 |
| Revenue | ★ $22,621,000,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | N/A | $57.13 |
| P/E Ratio | ★ $102.89 | $152.29 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $11.77 | $12.88 |
| 52 Week High | $26.10 | $80.98 |
Technical Indicators
Market Signals| Indicator | M | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 72.48 |
| Support Level | $21.80 | $31.23 |
| Resistance Level | $24.22 | N/A |
| Average True Range (ATR) | 0.91 | 4.24 |
| MACD | -0.33 | 0.00 |
| Stochastic Oscillator | 12.01 | 93.27 |
Price Performance
Historical ComparisonAbout M Macy's Inc
Founded in 1858 and based in New York City, Macy's operates about 430 eponymous stores, 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's names, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constituted 64% of 2025 net retail sales.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.